European Heart Journal Advance Access originally published online on October 30, 2006
European Heart Journal 2006 27(23):2823-2832; doi:10.1093/eurheartj/ehl337
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemodynamic and clinical effects of ularitide in decompensated heart failure
1 Kerckhoff-Klinik, Bad Nauheim, Germany
2 Department of Cardiology, Institute for Cardiovascular Diseases, University Medical Center of Serbia, Belgrade, Serbia
3 ‘Zvezdara’, University Clinical and Medical Center, Belgrade, Serbia
4 Russian Peoples Friendship University, Moscow, Russian Federation
5 Hospital St. Vincenz, Limburg, Germany
6 Division of Experimental and Clinical Peptide Research, Center of Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany
7 CardioPep Pharma GmbH, Karl-Wiechert-Allee 76, D-30625 Hannover, Germany
Received 18 May 2006; revised 18 August 2006; accepted 5 October 2006; online publish-ahead-of-print 30 October 2006.
* Corresponding author. Tel: +49 511 53045 18; fax: +49 511 53045 10. E-mail address: mmeyer{at}cardiopep.de
Aims Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF.
Methods and results In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension.
Conclusion Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF.
Key Words: Natriuretic peptide • Urodilatin • Ularitide • Decompensated heart failure • Congestive heart failure • Randomized clinical trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., September 2, 2008; 1(35): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., March 4, 2008; 1200(1): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., March 4, 2008; 1(9): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazory and E. A. Ross Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective Circulation, February 19, 2008; 117(7): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF]
|
|